Skip to main content
. Author manuscript; available in PMC: 2016 May 2.
Published in final edited form as: J Neurotrauma. 2011 Dec 20;29(3):539–550. doi: 10.1089/neu.2011.1976

FIG. 8.

FIG. 8

CD11d monoclonal antibody (mAb) treatment reduces the collagenous scar 42 days after spinal cord injury. (A) Trichrome staining was used to delineate the presence of collagen (blue color). Representative photomicrographs demonstrate large amounts of collagen at the injury site in CD11d and 1B7 mAb-treated mice. Rostral and caudal to their lesion epicenters, the CD11d mAb-treated mice had reduced levels of blue-stained collagen compared to the 1B7 control section, and almost no collagen was present in sections 640 μm rostral and 640 μm caudal to their lesion epicenters. (B) The area of collagen was reduced with CD11d mAb treatment (gray bars), rostral to the lesion site (−640 μm) and caudal to the lesion site (+320 μm), compared to controls (1B7, open bars; scale bar in A = 100 μm). (B) Values are means ± standard error (*significantly different from controls, p<0.0001 by one-way analysis of variance, and p<0.05 by Student Newman-Keuls test; 5 mice/1B7 group, 6 mice/anti-CD11d group).